Digital Catheter Based Pancreatoscopy (SpyGlassDS) for the Management of Symptomatic Pancreatic Duct Stones in Selected Patients With Chronic Pancreatitis

Pancreatitis, Chronic Clinical Trial

Official title:

Digital Catheter Based Pancreatoscopy (SpyGlassDS) for the Management of Symptomatic Pancreatic Duct Stones in Selected Patients With Chronic Pancreatitis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04131010
• Other study ID #: SPYGlass DS
• Status: Recruiting
• Phase: N/A
• Start date: May 31, 2019
• Est. completion date: December 2022

Study information

• Verified date: October 2019
• Source: Evangelisches Krankenhaus Düsseldorf
• Contact: Christian Gerges, Dr.
• Phone: +49 211 919 1605
• Email: Christian.Gerges[@]evk-duesseldorf.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Investigation of the efficacy and safety of digital catheter-based pancreatoscopy (DCP) for the Treatment of symptomatic Stones of the pancreatic duct in selected patients with chronic calcifying pancreatitis (CCP)

Description:

Background Endoscopic treatment of patients with chronic calcifying pancreatitis (CCP) is still challenging and controversially discussed. The goal is symptom control and relief of pain, which can be achieved by draining an obstructed main pancreatic duct (MPD) and/or removal of ductal stones. The 2012 European Society of Gastrointestinal Endoscopy (ESGE)- Guidelines recommends ESWL as a first step for patients with uncomplicated painful chronic pancreatitis and radiopaque stones ≥5mm obstructing the MPD. However, limitations of ESWL (extracorporeal shockwave lithotripsy ) include its limited availability, a likely need for multiple sessions and often repeated ERCP (endoscopic retrograde cholangiopancreatography) sessions for removal of stone fragments or treatment of associated strictures.

Pancreatoscopically guided management of pancreatic stones offers a potential alternative to ESWL. However, the numbers of studies and enrolled patients are still low. In 2015 single operator video cholangioscopy (SpyGlassDS, Boston Scientific) was introduced. Available data on its use for pancreatoscopy is limited. The technique provides digital imaging with a higher resolution and improved maneuverability compared to the legacy fiberoptic system. In addition, the working channel was enlarged to a diameter of 1.3 mm. Although SOVP have shown promise in CCP, studies to date generally have been limited by: retrospective design, relatively small and mixed patient populations, short follow-up periods, different clinical and technical endpoints, and, often, a single-center design. Therefore, the investigators designed a prospective multicenter cohort study to evaluate long-term clinical efficacy, technical success and safety of SOVP.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 43
• Est. completion date: December 2022
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Eligible patients are adults (= 18 years of age) with a signed informed consent with:

• symptomatic chronic pancreatitis (recurrent pain attacks, history of pain for at least 3 months), and

• =3 radiopaque stones =5mm obstructing the MPD in the pancreatic head and/or corpus.

Exclusion Criteria:

• - Health status ASA 4

• Pregnancy

• Coagulopathy (INR=2.0, Platelets < 70/nl)

• Taking anti-platelet agents or anticoagulants (other than aspirin) within last 7 days

• Any medical contraindication to ERCP, deep sedation or general anesthesia

• History of chronic symptomatic pancreatitis of more than 3-4 years[9]

• History of daily use of opioids except Tramadol for more than 6 months in the last 2 years

• Episode of biliary obstruction in the previous 2 months (defined as jaundice or bilirubin levels >=2,5mg/dl or CBD stent

• Auto-Immune Pancreatitis or IgG4 associated pancreatitis

• Altered GI anatomy, previous failures of endoscopic approach to the papilla

• Abdominal pain not attributable to CP

• Any suspicion of pancreatic cancer

• Current symptomatic WON

• More than one ductal stricture in the pancreatic head or body

• Previous ESWL pancreatic stones

• Age <18

Related Conditions & MeSH terms

• Pancreatitis
• Pancreatitis, Calcific
• Pancreatitis, Chronic

Intervention

Device:
• single operator video cholangioscopy
The technique provides digital imaging with a higher resolution and improved maneuverability compared to the legacy fiberoptic system. In addition, the working channel was enlarged to a diameter of 1.3 mm. Retrospective data showed an overall technical success rate for single-operator video pancreatoscopy (SOVP) guided treatment of pancreatic stones of 95%

Locations

Country	Name	City	State
Germany	Evangelisches Krankenhaus Düsseldorf	Düsseldorf	NRW

Sponsors (1)

Lead Sponsor	Collaborator
Evangelisches Krankenhaus Düsseldorf

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with complete clearance of the MPD from =3 stones in the pancreatic head and/or body by means of SOVP in =3 treatment sessions	Number of patients where complete clearance of the MPD could be reached within three Treatment sessions of SOVP	at baseline visit
Secondary	Number of treatment sessions	Number of Treatment sessions which are necessary to reach complete clearanceof the MPD	within three months
Secondary	Procedural time	Time for the procedure from beginning to the end of the intervention	at baseline visit
Secondary	Number of participants with Adverse events (post procedure and at 30 days)	Incidence of Treatment-emergent Adverse Events as reported by the patients or as detected during the visits or by unplanned hospitalization	at baseline visit and 30 days after the invention
Secondary	Rate of pancreatoscopic visualization of the targeted stones(s) and initiation of lithotripsy by using the Single-Operator Video pancreatoscopy (SOVP)	Determined by number of patients where the targeted Stones can be made visuable during the intervention	at baseline visit
Secondary	Number of patients with stone fragmentation (particles =3mm, or decreased stone density at X-ray, an increased stone surface and heterogenity of the stone(s) which may fill the MPD and adjacent side branches	Number of patients where the Stones can be fragmented during the intervention	at baseline visit
Secondary	Number of patients with ductal drainage after complete or incomplete ductal clearance (e.g. by placement of an endoprosthesis)		at baseline visit
Secondary	Determination by MRCP of the diameter of the MPD prior to treatment and at 6 months after the final intervention		prior procedure and 6 months after procedure
Secondary	Rate of patients with improved Clinical Outcome or complications as assessed by Numeric Rating scale (NRS) for pain, Izbicki Pain Score and number of pain attacks determined at 30 days, 6 and 12 months after the final intervention by means of SOVP	Self-reported pain Status as assessed by the pain assessments NRS for pain and Izbicki pain Score as well as self-reported pain attacks	30 days, 6 months and 12 months after procedure
Secondary	Change of Quality of life as assessed by the Short Form -12 questionnaire prior to treatment and 6 months after the final intervention	Self-reported Quality of life as assessed by the Short Form -12 questionnaire (this questionnaire is evaluated centrally by the rights-holding company), answering 12 questions regarding Quality of Life	prior treatrment, 6 months after treatment and at the last procedure visit (procedure I, II or III as applicable)